These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 17264340

  • 21. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group.
    N Engl J Med; 2006 Jan 05; 354(1):34-43. PubMed ID: 16394300
    [Abstract] [Full Text] [Related]

  • 22. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer.
    Yen MS, Twu NF, Lai CR, Horng HC, Chao KC, Juang CM.
    Gynecol Oncol; 2009 Sep 05; 114(3):415-9. PubMed ID: 19577277
    [Abstract] [Full Text] [Related]

  • 23. Intraperitoneal chemotherapy for advanced epithelial ovarian malignancy: lessons learned.
    Bunting M, Chan W, Brand A, Blomfield P.
    Aust N Z J Obstet Gynaecol; 2009 Dec 05; 49(6):667-71. PubMed ID: 20070720
    [Abstract] [Full Text] [Related]

  • 24. Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment.
    Le T, Leis A, Pahwa P, Wright K, Ali K, Reeder B, Hopkins L, Fung MF.
    Gynecol Oncol; 2004 Mar 05; 92(3):839-44. PubMed ID: 14984950
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
    Bottomley A, Biganzoli L, Cufer T, Coleman RE, Coens C, Efficace F, Calvert HA, Gamucci T, Twelves C, Fargeot P, Piccart M, European Organization for Research and Treatment of Cancer Breast Cancer Group.
    J Clin Oncol; 2004 Jul 01; 22(13):2576-86. PubMed ID: 15226325
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer.
    Kothari R, Nagel C, Koopmeiners JS, Ivy JJ, Geller M, Salani R, Argenta PA.
    Gynecol Oncol; 2010 Dec 01; 119(3):491-5. PubMed ID: 20888625
    [Abstract] [Full Text] [Related]

  • 32. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.
    Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH, Eastern Cooperative Oncology Group.
    J Clin Oncol; 2003 Apr 15; 21(8):1536-43. PubMed ID: 12697878
    [Abstract] [Full Text] [Related]

  • 33. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J.
    Gynecol Oncol; 2009 Aug 15; 114(2):199-205. PubMed ID: 19446314
    [Abstract] [Full Text] [Related]

  • 34. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Alvarez Secord A, Rubin SC, Mannel RS.
    J Clin Oncol; 2019 Jun 01; 37(16):1380-1390. PubMed ID: 31002578
    [Abstract] [Full Text] [Related]

  • 35. [Intraperitoneal chemotherapy for ovarian cancer].
    Noma J, Yoshida N.
    Gan To Kagaku Ryoho; 2008 Jun 01; 35(6):885-90. PubMed ID: 18633214
    [Abstract] [Full Text] [Related]

  • 36. Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications.
    Lesnock JL, Richard SD, Zorn KK, Krivak TC, Beriwal S, Sukumvanich P, McBee WC, Kelley JL, Edwards RP.
    Gynecol Oncol; 2010 Mar 01; 116(3):345-50. PubMed ID: 19959211
    [Abstract] [Full Text] [Related]

  • 37. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
    Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P, After 6 Italian Cooperative Group.
    J Clin Oncol; 2009 Oct 01; 27(28):4642-8. PubMed ID: 19704064
    [Abstract] [Full Text] [Related]

  • 38. Quality of life in ovarian cancer patients receiving chemotherapy.
    Lakusta CM, Atkinson MJ, Robinson JW, Nation J, Taenzer PA, Campo MG.
    Gynecol Oncol; 2001 Jun 01; 81(3):490-5. PubMed ID: 11371144
    [Abstract] [Full Text] [Related]

  • 39. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.
    Long HJ, Monk BJ, Huang HQ, Grendys EC, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV, Gynecologic Oncology Group.
    Gynecol Oncol; 2006 Mar 01; 100(3):537-43. PubMed ID: 16216315
    [Abstract] [Full Text] [Related]

  • 40. Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Hoppenau B, du Bois A, AGO-OVAR.
    Gynecol Oncol; 2006 Feb 01; 100(2):300-7. PubMed ID: 16199079
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.